PARP/Apoptosis Universal Colorimetric Assay Kit

For the in vitro screening of candidate PARP-1 inhibitors
Catalog # Availability Size / Price Qty
4677-096-K
Inhibition of PARP Activity by 3-aminobenzamide_4677-096-K
1 Image
Product Details
Citations (24)
FAQs
Reviews

PARP/Apoptosis Universal Colorimetric Assay Kit Summary

Ideal for the in vitro screening of candidate PARP-1 inhibitors and determination of IC50 values.

Key Benefits

• Colorimetric readout
• 96 strip-well format
• Sensitive – detects 10 mU PARP /well
• Assay Time ~3 hrs

Why Use the PARP/Apoptosis Colorimetric Assay Kit?

This ELISA based assay detects biotinylated poly (ADP-ribose) deposited by PARP-1 onto immobilized histones in a 96-well format. The addition of Strep-HRP (biotin-binding protein) and a colorimetric HRP substrate yields relative absorbance that correlates with PARP-1 activity.

Product Specifications

For the in vitro screening of candidate PARP-1 inhibitors and determination of IC50 values.

Kit Contents

• 3-Aminobenzamide
• PARP-HSA, 10 Units/µl
• 20X PARP Buffer
• 10X PARP Cocktail
• 10X Activated DNA
• 10X Strep-Diluent
• Histone-Coated Plate Natural Strip Well Plate
• Strep-HRP
• TACS-Sapphire

Specifications

Shipping Conditions
The components for this kit may require different storage/shipping temperatures and may arrive in separate packaging. Upon receipt, store products immediately at the temperature recommended on the product labels.
Storage
Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
Species
Multi-species

Limitations

For research use only. Not for diagnositic use.

Product Datasheets

Data Example

Inhibition of PARP Activity by 3-aminobenzamide. Graphical representation of the colorimetric readout of a PARP standard curve (A) and an inhibition curve for the PARP inhibitor 3-aminobenzamide (provided in the kit). (B) The standard curve is used to translate absorbance values to activity units of PARP.

Citations for PARP/Apoptosis Universal Colorimetric Assay Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

24 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
    Authors: H Li, J Tu, Z Zhao, L Chen, Y Qu, H Li, H Yao, X Wang, DF Lee, J Shen, L Wen, G Huang, X Xie
    Theranostics, 2020;10(21):9477-9494.  2020
  2. Inhibition of NADPH oxidase alleviates germ cell apoptosis and ER stress during testicular ischemia reperfusion injury
    Authors: F Al-Saleh, F Khashab, F Fadel, N Al-Kandari, M Al-Maghreb
    Saudi J Biol Sci, 2020;27(8):2174-2184.  2020
  3. Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model
    Authors: RW Li, Y Deng, HN Pham, S Weiss, M Chen, PN Smith
    Injury, 2019;0(0):.  2019
  4. Increased error-free DNA repair gene expression through reprogramming in human iPS cells
    Authors: Y Yoshimura
    Regen Ther, 2019;11(0):101-105.  2019
  5. Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2
    Authors: C Wang, W Xu, J An, M Liang, Y Li, F Zhang, Q Tong, K Huang
    Nat Commun, 2019;10(1):1203.  2019
  6. The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition
    Authors: S Alqahtani, K Welton, JP Gius, S Elmegerhi, TA Kato
    Int J Mol Sci, 2019;20(6):.  2019
  7. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.
    Authors: Jouan-Lanhouet S, Arshad M, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F, Takahashi N, Sergent O, Lagadic-Gossmann D, Vandenabeele P, Samson M, Dimanche-Boitrel M
    Cell Death Differ, 2012;19(12):2003-14.  2012
  8. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.
    Authors: Mathews MT, Berk BC
    Arterioscler. Thromb. Vasc. Biol., 2008;28(4):711-7.  2008
  9. Histone H2AX is a critical factor for cellular protection against DNA alkylating agents.
    Authors: Meador JA, Zhao M, Su Y, Narayan G, Geard CR, Balajee AS
    Oncogene, 2008;27(43):5662-71.  2008
  10. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus.
    Authors: Ma W, Halweg C, Menendez D, Resnick M
    Proc Natl Acad Sci U S A, 0;109(17):6590-5.  0
  11. Silencing of poly(ADP-ribose) polymerase-1 suppresses hyperstretch-induced expression of inflammatory cytokines in vitro.
    Authors: Wang J, Liu L, Xia Y, Wu D
    Acta Biochim Biophys Sin (Shanghai), 0;46(7):556-64.  0
  12. BCL2 suppresses PARP1 function and nonapoptotic cell death.
    Authors: Dutta C, Day T, Kopp N, van Bodegom D, Davids M, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown J, Shapiro G, Letai A, Weinstock D
    Cancer Res, 0;72(16):4193-203.  0
  13. PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
    Authors: Zakaria E, El-Maraghy N, Ahmed A, Ali A, El-Bassossy H
    Naunyn Schmiedebergs Arch Pharmacol, 0;390(6):621-631.  0
  14. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
    Authors: Jasek E, Gajda M, Lis G, Jasinska M, Litwin J
    Anticancer Res, 0;34(4):1849-56.  0
  15. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
    Authors: Jelinic P, Levine D
    Mol Cancer Ther, 0;13(6):1645-54.  0
  16. Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1.
    Authors: Chen Y, Bang S, Park S, Shi H, Kim S
    Biochem J, 0;469(2):189-98.  0
  17. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1).
    Authors: Noren Hooten N, Kompaniez K, Barnes J, Lohani A, Evans M
    J Biol Chem, 0;286(52):44679-90.  0
  18. Poly(ADP-ribose) polymerase 1 promotes oxidative-stress-induced liver cell death via suppressing farnesoid X receptor alpha.
    Authors: Wang C, Zhang F, Wang L, Zhang Y, Li X, Huang K, Du M, Liu F, Huang S, Guan Y, Huang D, Huang K
    Mol Cell Biol, 0;33(22):4492-503.  0
  19. Nitric oxide modulates hypoxia-inducible factor-1 and poly(ADP-ribose) polymerase-1 cross talk in response to hypobaric hypoxia.
    Authors: Martinez-Romero R, Canuelo A, Siles E, Oliver F, Martinez-Lara E
    J Appl Physiol (1985), 0;112(5):816-23.  0
  20. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.
    Authors: Rajesh M, Batkai S, Kechrid M, Mukhopadhyay P, Lee W, Horvath B, Holovac E, Cinar R, Liaudet L, Mackie K, Hasko G, Pacher P
    Diabetes, 0;61(3):716-27.  0
  21. Disruption of Wnt/beta-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
    Authors: Kulak O, Chen H, Holohan B, Wu X, He H, Borek D, Otwinowski Z, Yamaguchi K, Garofalo L, Ma Z, Wright W, Chen C, Shay J, Zhang X, Lum L
    Mol Cell Biol, 0;35(14):2425-35.  0
  22. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
    Authors: To C, Kim E, Royce D, Williams C, Collins R, Risingsong R, Sporn M, Liby K
    Cancer Prev Res (Phila), 0;7(7):698-707.  0
  23. Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
    Authors: Trafalis D, Polonifi A, Dalezis P, Nikoleousakos N, Katsamakas S, Sarli V
    Chem Biol Drug Des, 0;90(5):854-866.  0
  24. Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.
    Authors: Thurber G, Reiner T, Yang K, Kohler R, Weissleder R
    Mol Cancer Ther, 0;13(4):986-95.  0

FAQs

  1. With what species does this kit work?

    • This kit is not species specific. It is suitable for enzymes that will be conserved across all mammals and for tissue homogenates.

  2. What PARP isoform is detected in this kit?

    • This is a universal PARP kit. We expect that all 3 isoforms of PARP will be detected by this kit.

  3. Is the kit capable of measuring PARP hyperactivation (ie. greater than 100% of the PARP positive control)?

    • With this kit, hyperactivation may be possible since it is a cell free system. It is possible that test molecules increase the binding of PARP to the activated DNA or inhibit its dissociation. We are unable to confirm if PARP may become bound to the DNA and trapped within the replication fork or if this would allow for hyperactivation.

  4. What is the ratio of NAD and activated DNA relative to the concentration of enzyme in the final well?

    • The ratio of PARP to DNA is 2:1 and NAD is in excess in the final well.

View all FAQs

Reviews for PARP/Apoptosis Universal Colorimetric Assay Kit

There are currently no reviews for this product. Be the first to review PARP/Apoptosis Universal Colorimetric Assay Kit and earn rewards!

Have you used PARP/Apoptosis Universal Colorimetric Assay Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review